Egypt aims to achieve $3 billion in pharmaceutical exports by 2030, according to Chairman of the Egyptian Drug Authority (EDA) Ali El-Ghamrawy, an Egyptian Cabinet statement reported on Monday. El-Ghamrawy joined a high-level delegation of 11 Latin American ambassadors in a visit to GYPTO Pharma, Egypt's leading pharmaceutical city. He said the country is committed to strengthening cooperation with Latin American nations in the pharmaceutical industry to enhance strategic partnerships and expand export markets. He stressed Egypt's strong pharmaceutical industry, meeting 91.3 per cent of domestic medicine needs and exporting to 147 countries. El-Ghamrawy provided an overview of Egypt's pharmaceutical market, which includes over 170 human medicine factories, 116 medical device manufacturers, and four facilities producing raw materials and biological products. He highlighted that the EDA has obtained 11 international accreditations in the last five years. He also emphasised Egypt's status as the first African nation to achieve the World Health Organisation's (WHO) maturity level 3 (ML3) for drug and vaccine manufacturing, ensuring compliance with the highest international standards. Chairman of GYPTO Pharma, Amr Mamdouh, reiterated that the state-owned facility was established to provide high-quality, affordable medicines. He revealed the company's intention to collaborate with Latin American nations in co-manufacturing and exporting top-notch medicines, highlighting that GYPTO Pharma is currently producing 65 million packs of medications annually. The diplomatic delegation praised Egypt's pharmaceutical system and expressed interest in developing pharmaceutical relations with the country. They appreciated the capabilities and technology of GEPTO Pharma and aimed to establish partnerships in various pharmaceutical fields. Attribution: Amwal Al Ghad English Subediting: M. S. Salama
